K-numberK250151
Device nameUs2.ca
ApplicantEko.Ai Pte Ltd. D/B/A Us2.Ai
Product codeSDJ
Device classClass II
Decision dateJun 20, 2025
DecisionSubstantially Equivalent
Regulation870.2200
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Us2.ca is an AI-powered image analysis software that processes transthoracic cardiac ultrasound images to help qualified cardiologists, sonographers, and healthcare practitioners diagnose cardiac amyloidosis. It is intended for adult patients with increased left ventricular wall thickness (interventricular septal thickness or left ventricular posterior wall thickness ≥12mm) and serves as a clinical decision-support tool, not a standalone diagnostic device.

Technological characteristics

Both Us2.ca and the predicate device (EchoGo Cardiac Amyloidosis 1.0) are Class II adjunctive cardiovascular status indicators using machine learning algorithms to analyze DICOM-formatted echocardiographic images. Both devices are software-as-a-medical-device (SaMD) hosted on third-party cloud infrastructure. Key differences include Us2.ca's expanded intended population (all adults, not just those ≥65 years) and broader user base (sonographers and licensed practitioners, not only interpreting clinicians).

Test standards cited

The submission references AAMI/ANSI HE75 standards for human factors and usability engineering assessment. FDA guidance documents on cybersecurity management, software changes, and 510(k) decision-making are cited. Internal verification and validation testing, regression testing, and design control processes are described, but specific ISO, IEC, or ASTM consensus standards are not explicitly identified in this summary.

Substantial equivalence argument

Both devices target cardiac amyloidosis detection using machine learning on echocardiographic data and share the same regulatory classification and product code. Us2.ca's differences in intended population age range and user types do not create new safety or effectiveness questions because the device operates on the same technological principle, uses comparable performance metrics (sensitivity 86.9%, specificity 87.4%), and demonstrates substantial equivalence through extensive external validation across multiple clinical sites and ultrasound vendors with results meeting established benchmarks and subgroup consistency across demographics and systems.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →